A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Inclusion Criteria: * Patients with advanced/metastatic high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer\*: 1. who has undergone ≥2 previous chemotherapy regimen; 2. with confirmed platinum resistance\*\*; 3. ≥3 month PARP inhibitor treatment history; 4. confirmed BRCA1/2 mutation \*\*\* or HRD \*\*\*\* * Subjects with at least one measurable lesion in accordance with RECIST v1.1 * Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Subjects with life expectancy ≥12 weeks * Patients with adequate hematologic, kidney, and liver functions confirmed using the following criteria (retesting of laboratory tests is allowed once during screening) * Subjects who voluntarily decided to participate in this study after being fully informed and gave informed consent Exclusion Criteria: * Subjects who meet any of the following conditions cannot participate in this study: 1. Subjects with a history of severe drug hypersensitivity or the hypersensitivity to IP and its ingredients or similar drugs 2. Subjects with dysphagia 3. Subjects confirmed with the following medical or surgical/procedural history: * Primary malignant tumor other than ovarian cancer diagnosed or treated within 24 months prior to baseline (individuals with successfully treated cutaneous basal/squamous cell carcinoma are eligible for enrollment) * Major surgery requiring general anesthesia or respiratory support within 4 weeks prior to baseline (2 weeks for video-assisted thoracoscopic surgery \[VATS\] or open-and-closed \[ONC\] surgery) * Severe cardiovascular disease (e.g., myocardial infarction and unstable angina) that occurred within 24 weeks prior to baseline * New York Heart Association Class 3 or 4 heart failure within 24 weeks prior to baseline * Severe cerebrovascular disease observed within 24 weeks prior to baseline * Pulmonary thrombosis or deep vein thrombosis within 24 weeks prior to baseline, or bronchial asthma, obstructive pulmonary disease, or other serious, life-threatening lung disease (e.g., acute respiratory distress syndrome and lung failure) considered ineligible for study participation * Infections requiring treatment, such as systemic antibiotics and antivirals, within 2 weeks prior to baseline, or other uncontrolled ≥Grade 3 active infectious diseases * Symptomatic interstitial lung disease * Subjects who showed poor recovery from hematologic toxicity in the past chemotherapy (e.g., ≥grade 3 toxicity for ≥4 weeks) * Bone marrow or stem cell transplantation with high-dose chemotherapy * Total gastrectomy or total duodenectomy * Individuals with a history of myelodysplastic syndrome (MDS) or pretreatment cytogenetic test results indicating a risk of MDS/acute myeloid leukemia (AML) 4) Subjects with the following concurrent conditions: * Subjects with clinically significant symptoms or uncontrolled central nervous system or brain metastases (except when systemic corticosteroid administration was stopped at least 4 weeks prior to baseline and was stable for ≥4 weeks) * Subjects who have confirmed clinically significant conditions in the electrocardiogram (ECG) according to the investigator's judgment * Uncontrolled hypertension (systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg) * Bleeding diatheses * Active hepatitis B or C virus infection (patients with hepatitis may participate if HBV DNA and HCV RNA are below the lower limit of detection established by the study site) * Known human immunodeficiency virus infection (HIV) positive * Subjects with neurological and psychiatric disorders severe enough to affect the study results according to the investigator's judgment 5) Subjects who have the following drug treatment history: * Subjects who have received chemotherapy†, immunotherapy (including biologics), hormone therapy, or therapeutic/palliative radiotherapy‡ within 4 weeks prior to baseline * Subjects who require continuous (≥4 weeks) treatment of systemic corticosteroids equivalent to prednisone \>10 mg/day * Subjects who were treated with antithrombotic drugs, including antiplatelet agents and anticoagulants, within 2 weeks from baseline or are expected to be treated with them during the study period (however, low molecular weight heparin \[LMWH\]) treatment is allowed) * Subjects who require continuous administration of non-steroidal anti-inflammatory drugs (NSAIDs), which have high risk of bleeding 6) Pregnant or lactating women, or women of childbearing potential who do not intend to abstain or use appropriate contraceptive methods\* during the study period and up to 3 months after IP administration \*Appropriate contraception: 7) Subjects who have taken or undergone another IP or investigation device within 4 weeks prior to baseline 8) subjects who are judged by the investigator as ineligible for study participation